The Pfizer-Wyeth merger will mean changes for its meetings department. What they may be, however, is still up in the air.
Pfizer completed its $67 billion acquisition of Wyeth Pharmaceuticals last fall, just one in a string of recent mergers and acquisitions in the pharma industry. When asked how the two meetings departments would be affected and how procurement and sourcing would be handled, Joan Campion, a spokeswoman for Pfizer, declined to get specific: “I can tell you that Pfizer is continuing to evaluate its global workforce, which includes our medical meetings group, to determine how best to support ...
Register for Complete Access (Valid Email Required)
By registering on MeetingsNet now, you'll not only gain access to Pfizer-Wyeth Merger and Meetings, you'll get exclusive access to a large archive of premium content.